Literature DB >> 30864668

Validation and Application for the Berlin Grading System of Moyamoya Disease in Adult Patients.

Mario Teo1,2, Sunil Furtado1, Osamu F Kaneko3, Tej D Azad1, Venkatesh Madhugiri1, Huy M Do1,3, Gary K Steinberg1.   

Abstract

BACKGROUND: Traditional moyamoya disease (MMD) classification relies on morphological digital subtraction angiography (DSA) assessment, which do not reflect hemodynamic status, clinical symptoms, or surgical treatment outcome.
OBJECTIVE: To (1) validate the new Berlin MMD preoperative symptomatology grading system and (2) determine the clinical application of the grading system in predicting radiological and clinical outcomes after surgical revascularization.
METHODS: Ninety-six MMD patients (192 hemispheres) with all 3 investigations (DSA, magnetic resonance imaging [MRI], Xenon-CT) performed preoperatively at our institution (2007-2013) were included. Two clinicians independently graded the imaging findings according to the proposed criteria. Patients' modified Rankin Score (mRS) scores (preoperative, postoperative, last follow-up), postoperative infarct (radiological, clinical) were collected and statistical correlations performed.
RESULTS: One hundred fifty-seven direct superficial temporal artery-middle cerebral artery bypasses were performed on 96 patients (66 female, mean age 41 yr, mean follow-up 4.3 yr). DSA, MRI, and cerebrovascular reserve capacity were independent factors associated hemispheric symptomatology (when analyzed individually or in the combined grading system). Mild (grade I), moderate (grade II), severe (grade III) were graded in 45, 71, and 76 hemispheres respectively; of which, clinical symptoms were found in 33% of grade I, 92% of grade II, 100% of grade III hemispheres (P < .0001). Two percent of grade I, 11% of grade II, 20% of grade III hemispheres showed postoperative radiological diffusion weighted image-positive ischemic changes or hemorrhage on MRI (P = .018). Clinical postoperative stroke was observed in 1.4% of grade II, 6.6% of grade III hemispheres (P = .077). The grading system also correlated well to dichotomized mRS postoperative outcome.
CONCLUSION: The Berlin MMD grading system is able to stratify preoperative hemispheric symptomatology. Furthermore, it correlated with postoperative new ischemic changes on MRI, and showed a strong trend in predicting clinical postoperative stroke.
Copyright © 2019 by the Congress of Neurological Surgeons.

Entities:  

Keywords:  Moyamoya disease; hemispheric symptomatology; modified Rankin Score; new grading system; postoperative risk; radiological outcome

Mesh:

Year:  2020        PMID: 30864668     DOI: 10.1093/neuros/nyz025

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  5 in total

1.  The Significance and Challenge of Quantitative Hemodynamic Study in Moyamoya Disease.

Authors:  J Yu; Q Du; J Chen
Journal:  AJNR Am J Neuroradiol       Date:  2020-07-16       Impact factor: 3.825

2.  Hypo-high density lipoproteinemia is a predictor for recurrent stroke during the long-term follow-up after revascularization in adult moyamoya disease.

Authors:  Xiaofan Yu; Peicong Ge; Yuanren Zhai; Rong Wang; Yan Zhang; Dong Zhang
Journal:  Front Neurol       Date:  2022-07-26       Impact factor: 4.086

3.  Current trends in pediatric moyamoya: a survey of international practitioners.

Authors:  Harishchandra Lalgudi Srinivasan; Moran Hausman-Kedem; Edward R Smith; Shlomi Constantini; Jonathan Roth
Journal:  Childs Nerv Syst       Date:  2021-03-10       Impact factor: 1.475

4.  Surgical Management of Failed Revascularization in Moyamoya Vasculopathy.

Authors:  Kristin Lucia; Güliz Acker; Nicolas Schlinkmann; Stefan Georgiev; Peter Vajkoczy
Journal:  Front Neurol       Date:  2021-06-29       Impact factor: 4.003

Review 5.  Progression in Moyamoya Disease: Clinical Features, Neuroimaging Evaluation, and Treatment.

Authors:  Xin Zhang; Weiping Xiao; Qing Zhang; Ding Xia; Peng Gao; Jiabin Su; Heng Yang; Xinjie Gao; Wei Ni; Yu Lei; Yuxiang Gu
Journal:  Curr Neuropharmacol       Date:  2022       Impact factor: 7.708

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.